|
110 Little Falls Rd. Fairfield, NJ 07004 NJ Tel. 973-882-0860 Fax 973-882-8277 |
Type: Public
On the web:
http://www.unigene.com
Employees:
103
Employee growth: 3.0%
Unigene Laboratories has a unified focus: peptides. Its core products are based on the two hormones calcitonin and parathyroid hormone (PTH), both natural peptides useful in treating osteoporosis. Unigene has developed a patented process for the efficient production of the peptides and has developed oral and nasal drug delivery technologies. Partner GlaxoSmithKline is developing oral PTH, which is in early-stage clinical trials. Unigene's nasal calcitonin product, branded as Fortical, has won FDA approval; Upsher-Smith Laboratories markets the drug for the US osteoporosis market. Unigene has also licensed its peptide production process to Novartis, allowing the company to produce its own calcitonin.
Key numbers for fiscal year ending December, 2008:
Sales: $19.2M
One year growth: (5.8%)
Net income: ($6.1)M
Officers:
Chairman and Treasurer: Jay Levy
President, CEO, and Director: Warren P. Levy
VP Finance: William J. (Bill) Steinhauer
